Milestone Pharmaceuticals (MIST) Cash & Equivalents (2018 - 2026)

Milestone Pharmaceuticals (MIST) has 9 years of Cash & Equivalents data on file, last reported at $71.3 million in Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $71.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.3 million (changed N/A YoY) and the FY2025 annual result came in at $73.0 million, up 188.56% from the prior year.
• Cash & Equivalents retreated to $71.3 million in Q1 2026, from $73.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $101.0 million in Q1 2023 to a low of $7.6 million in Q4 2022.
• A 5-year average of $55.9 million and a median of $63.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 93.31% — and 2025, when it surged 188.56%.
• Tracing MIST's Cash & Equivalents over 5 years: stood at $7.6 million in 2022, then surged by 80.2% to $13.8 million in 2023, then surged by 83.97% to $25.3 million in 2024, then surged by 188.56% to $73.0 million in 2025, then slipped by 2.37% to $71.3 million in 2026.
• The last three Cash & Equivalents figures came in at $71.3 million (Q1 2026), $73.0 million (Q4 2025), and $82.6 million (Q3 2025), per Business Quant data.